/target-data-sheets/cytokine/il17rd-tnfr2
3/28/2016 11:22:37 PM
/products/reagent/recombinant-human-il-17-(il-17a)-92-1229
CHALLENGE The client identified a novel IL-17 inhibitor as its lead compound to treat an autoimmune disease. Specifically, it had identified the compound in a phenotypic screen of mouse cells and tested it in a rodent model for Collagen-Induced Arthritis. At this point, our c...
/tools-resources/document-resource-library/documents/bioseek-economic-impact-of-biomap-profiling-bridgi
1/28/2013 5:00:01 PM
Th17 responses are critical to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise. Here, we report data to support selective bromodomain blockade of the transcriptional coactivato...
/tools-resources/publications-references/publications/bromodomain-inhibitor-cbp30-suppresses-th17
4/9/2019 8:54:22 AM
/products/reagent/recombinant-human-il-17f-92-1259
/products/cell-line/u2os-il17ra-il17rc-dimerization-cell-lin-93-0999c3
/products/assay/il17ra-il17rc-dimerization-bioassa-93-0999y3-00053
/products/assay/il17ra-il17rc-dimerization-bioassa-93-0999y3-00054
/products/assay/il17ra-il17rc-dimerization-assay-93-0931e1cp7m
/products/assay/il17ra-il17rc-dimerization-assay-93-0931e1cp7l
|<
<
1 2 3
>
>|
Pages: 1 of 3